Compare ImmunityBio Inc. Common Stock (IBRX) vs Nordic American Tankers Limited Common Stock (NAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Nordic American Tankers Limited Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $10.09 (market cap $10.39B), while Nordic American Tankers Limited Common Stock trades at $7.98 (market cap $1.86B). The key difference: ImmunityBio Inc. Common Stock is far larger — about 5.6× Nordic American Tankers Limited Common Stock's market cap, and Nordic American Tankers Limited Common Stock pays a 12.29% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 6 Days and Nordic American Tankers Limited Common Stock for 0 Days on average.
| IBRX | NAT | |
|---|---|---|
Market Cap | $10.39B | $1.86B |
Volume | 11,509,049 | 5,330,493 |
Sector | Health | Industrials |
52-Week High | $11.55 | $8.79 |
52-Week Low | $1.98 | $3.26 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.84B | $2.13B |
Dividend Yield | — | 12.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
NAT trades at $8.79, matching its 52-week high, reflecting strong momentum amid favorable tanker market conditions. The stock shows robust fundamentals with a 33.34% net income margin and 25.66% ROE for 2026, while Q2 2026 EPS beat expectations. Technical indicators are neutral, with support and resistance clustered around $9. Recent news highlights surging spot rates and insider buying by the Hansson family, underscoring confidence in near-term prospects.
Outlook is positive due to elevated freight rates and earnings growth, but risks include volatility in tanker rates and geopolitical tensions. Analysts are mixed with a $3.50 consensus target, suggesting caution despite operational strength. The stock's high yield and momentum offer appeal, though sustainability of current rates remains a key monitorable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Nordic American Tankers Limited Common Stock
Nordic American Tankers Limited is a Bermuda-based shipping company specializing exclusively in Suezmax crude-oil tankers, which it charters in the spot and period markets on international routes. The company has paid a dividend every quarter since 1997.
Read more on NAT →
